Chemours (CC) revenue and earnings history
Chemours reported revenue of $5.81B for fiscal 2025 (year ended Dec 31, 2025), +0.4% on the year before, and net income of −$386M.
Over 12 years, from fiscal 2013 to fiscal 2025, revenue grew at a compound rate of −1.4% a year.
Revenue and net income, 13 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $5.81B+0.4% | — | −$386M | $264M | $213M | $51M | $21M | — | $78M | $670M | $4.14B | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Chemours (CC) on OQRO.
Common questions
What was Chemours's revenue in fiscal 2025?
$5.81B for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 24, 2026. That is +0.4% on fiscal 2024 ($5.78B).
How fast has Chemours's revenue grown?
From $6.86B in fiscal 2013 to $5.81B in fiscal 2025: a compound annual growth rate of −1.4% over 12 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Chemours tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
